Oric Pharmaceuticals stock under pressure as daily decline signals short-term weakness

Traders Union
All News
Business & Wealth
Companies
Oric Pharmaceuticals slides 4.90% today

Highlights

ORIC trades above key moving averages, maintaining a bullish medium- and long-term technical structure despite recent short-term weakness.
Recent momentum indicators are mixed, with longer-term signals bullish but short-term oscillators suggesting oversold conditions and ongoing near-term pressure.
Expected trading range for the coming week is $11.00 to $12.70, with consolidation likely near support and strong probability of upward movement.

The company is advancing development of enozertinib, its brain-penetrant EGFR inhibitor for the potential treatment of non-small cell lung cancer.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish long-term structure as short-term trend weakens near support

ORIC is trading at $11.07, sitting just above the MA-20 ($11.05) and well above both the MA-50 ($9.66) and MA-200 ($10.58), indicating the short-term trend is under pressure but the broader medium- to long-term structure remains bullish. The Ichimoku Kijun level on D1 stands at $10.94, which is below the current price and thus acts as immediate support.

Divergent momentum signals amid heavy weekly losses and increased volatility

Momentum signals on D1 are notably bullish with MACD flashing a strong buy and ADX at 31.29 also in buy territory, but shorter-term moving averages signal sell, hinting at near-term weakness. RSI on D1 is neutral-to-positive at 53.72, while Stoch RSI is deeply oversold and CCI is neutral, revealing mixed sentiment and some divergence in oscillator signals. BBP on D1 shows buyer presence, but intraday momentum is negative based on lower timeframes. ORIC has fallen $1.03 (8.51%) over the past week, dropping from a previous weekly close of $12.10. The stock is at the very bottom of this week’s range near support. Weekly volatility stands at 14.27%, and the tone has been a steady decline from earlier highs. In today's session, ORIC declined 4.9%, marking a sharp move downward and increased short-term pressure.

Sideways consolidation favored as bullish outlook outweighs downside risk

For the coming week, the expected trading range is $11.00 to $12.70, reflecting both recent volatility and typical movement patterns. The probability of a price increase is high, at more than 80%, as three out of four key W1 signals (MA-50-W1, MA-100-W1, RSI-W1) are bullish. The likelihood of another weekly decline is therefore very low. Baseline scenario: ORIC consolidates sideways between $11.00 and $12.70, given oversold D1 oscillators and strong mid/long-term trend support. In a bullish scenario, a sustained move above $11.67 resistance could retest the $12.70 area, especially if daily momentum recovers. In a bearish scenario, a drop below $11.00 support could see the price drift toward the MA-50 ($9.66) as the next key support. Overall, the forecast range remains above the 52-week low of $7.32 and well below the 52-week high of $14.93, showing some recovery but resistance to upside continuation.

Previously it was reported that Oric Pharmaceuticals exhibited a bullish technical profile, but with caution due to mixed momentum signals and the potential for sideways or downward movement. The current article adds further perspective on Oric’s evolving outlook, and investors should closely monitor for any decisive shifts in price action that could indicate a new market trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.